More Articles

Generics prices in US decrease again in 2013 Reports | Posted 03/07/2015

In 2013, retail prices for 280 widely used generics fell by an average of 4.0%, compared to the US inflation rate, which was 1.5% over the same period.

Biosimilars licensing agreements for AMP and Formycon Biosimilars/News | Posted 03/07/2015

German biosimilars companies AMP Biosimilars (AMP) and Formycon have both made out-licensing agreements for their candidate biosimilars.

Indian pharma industry to get government support Generics/General | Posted 03/07/2015

In a bid to promote the manufacture of pharmaceuticals in the country, the Indian Government has announced plans to set up a Rs 500-crore venture capital fund to provide cheaper loans to firms look...

Polish firm gets EIB loan for biosimilars development Biosimilars/General | Posted 03/07/2015

The European Investment Bank (EIB) is lending Euros 45 million (around Zloty 185 million) to the largest Polish manufacturer of pharmaceuticals, Polpharma, for its research into, and developme...

Mylan launches generic asthma inhaler in UK Generics/News | Posted 03/07/2015

US generics manufacturer Mylan announced on 8 June 2015 that it had launched the first bioequivalent alternative to GlaxoSmithKline (GSK)’s asthma inhaler Seretide/Advair (fluticasone/salmeterol) i...

Concerns raised over Australian decision to substitute biosimilars Biosimilars/General | Posted 26/06/2015

In May 2015, Australia’s Pharmaceutical Benefits Advisory Committee (PBAC) recommended that originator biologicals could be substituted by biosimilars by physicians and pharmacists [1]. However, ph...

Approval of biosimilars in rheumatology Biosimilars/Research | Posted 26/06/2015

Biosimilars are approved following a regulatory pathway different to that of generics, as they are not molecularly identical to their reference products. Currently, only one biosimilar is approved...

Real-life results for Inflectra compared to Remicade Biosimilars/Research | Posted 26/06/2015

Results of a post-marketing clinical study of infliximab biosimilar Inflectra demonstrated equivalent effectiveness compared to the originator biological (Remicade) in patients with rheumatoid arth...